Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Trinity diagnostic news

TRIB will restructure and reduce headcount by about 80 (10%) to 760. The company also reduced its hemostasis product portfolio by 106 to 79 products, and its

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE